報價延遲最少15分鐘:2024/12/24 13:34 EST
|
|
|
|
|
||||||||||||
|
|
|
|
|
1.025 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-1.83/-1.93
|
|
企業價值
133.39M
|
| 資產負債 |
|
每股賬面淨值
2.30
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
2.24M
|
|
每股收益
0.05
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2024/12/24 13:34 EST
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Century Therapeutics Inc is a biotechnology company specializes in leveraging adult stem cells to develop advanced cell therapy products targeting cancer, autoimmune, and inflammatory diseases. Their innovative approach involves a genetically engineered allogeneic cell therapy platform comprising induced pluripotent stem cells (iPSCs), CRISPR-mediated precision gene editing, proprietary chimeric antigen receptors (CARs), Allo-EvasionTM technology, and cutting-edge manufacturing capabilities. This comprehensive platform aims to overcome the limitations of first-generation cell therapies by optimizing cell product performance, preventing rejection by the host immune system, and minimizing development and supply risks. |